Acute Hypoxemic Respiratory Failure Management

Definition and Clinical Presentation

Acute hypoxemic respiratory failure (AHRF) is characterized by hypoxemia with the clinical spectrum ranging from mild hypoxemia to full-blown acute respiratory distress syndrome (ARDS), according to the European Respiratory Society 1, 2
AHRF primarily involves oxygenation problems, though it can coexist with acute hypercapnic respiratory failure, which involves elevated CO2 levels, as noted by the Thorax journal 3, 4

The European Respiratory Society recommends a target oxygen saturation (SaO2) of 88-92% in all causes of AHRF 5
Conventional oxygen therapy (COT) options include nasal prongs, facemask with reservoirs, and Venturi mask, as suggested by the European Respiratory Journal 1
High-flow nasal cannula (HFNC) is suggested over conventional oxygen therapy in adults with AHRF, providing airflows up to 50-60 L/min, reliable achievement of FiO2 up to 100%, and low level of positive end-expiratory pressure (PEEP) in upper airways, according to the European Respiratory Journal 1, 2

HFNC has benefits including decreased risk of patient self-inflicted lung injury (P-SILI), carbon dioxide washout of upper airways, reliable humidification, and enhanced patient comfort, as noted by the European Respiratory Journal 1, 2
Invasive mechanical ventilation (IMV) is required when noninvasive strategies fail, as recommended by the European Respiratory Journal 1

Continuous oxygen saturation monitoring, intermittent measurement of pCO2 and pH, and ECG monitoring if pulse rate >120 bpm or if there is dysrhythmia are recommended, according to the Thorax journal 5

HFNC may reduce the need for intubation and escalation to noninvasive ventilation (NIV) compared to conventional oxygen therapy, with a risk ratio of 0.89 and 0.76 respectively, as noted by the European Respiratory Journal 1
HFNC reduces patient discomfort and dyspnea, and slightly lowers respiratory rate, according to the European Respiratory Journal 1
Mortality remains similar whether using HFNC or conventional oxygen therapy in the short term and at 90 days, as reported by the European Respiratory Journal 1

Avoid hyperoxygenation as it can be harmful in patients with AHRF, as warned by the Thorax journal 5
When providing NIV, oxygen enrichment should be administered as close to the patient as possible, and optimize ventilator settings before increasing FiO2, as recommended by the Thorax journal 5
High oxygen flow rates (>4 L/min) may cause mask leak and delayed triggering, potentially worsening patient-ventilator asynchrony, as noted by the Thorax journal 5

The American College of Physicians recommends using high-flow nasal oxygen (HFNO) rather than noninvasive ventilation (NIV) as first-line therapy for adults with acute hypoxemic respiratory failure, with reduced intubation rates and lower mortality compared to conventional oxygen therapy and NIV 6, 7, 8
The American College of Physicians also recommends using HFNO rather than conventional oxygen therapy for adults developing respiratory failure after extubation, with reduced reintubation rates and improved patient comfort 6, 8, 9

HFNO delivers warm, humidified oxygen at flows up to 60 L/min, providing decreased work of breathing and more efficient respiratory effort, as well as enhanced mucociliary clearance through optimal humidification 6, 9

HFNO demonstrates clear superiority over conventional oxygen therapy, with lower intubation rates, reduced need for escalation to more invasive support, and decreased dyspnea and patient discomfort 8
HFNO offers similar or lower intubation rates, better patient tolerance and comfort, and fewer complications compared to NIV for initial acute hypoxemic respiratory failure management 6, 8

The 2021 American College of Physicians guidelines represent the most recent high-quality evidence, based on systematic review of 29 randomized controlled trials, with conditional recommendations due to variation in trial populations and inadequate sample sizes 6, 7, 8